Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
| Business Activity | PASS |
| Debt Ratio (0.09%) | PASS |
| Cash Ratio (0.08%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-30 | -0.33 | Pending | -- |
| 2026-05-07 | -0.36 | 0.15 | +141.3% |
| 2026-02-24 | -0.39 | -0.47 | -19.4% |
| 2025-10-30 | 0.94 | 1.67 | +77.3% |
| 2025-07-31 | -0.47 | -0.33 | +29.8% |
| 2025-05-07 | -0.35 | -0.74 | -114.4% |
| 2025-02-28 | -0.41 | -0.29 | +29.3% |
| 2024-11-05 | -0.27 | -0.46 | -71.4% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $268.3M | $18.7M | $29.8M | $227.7M | $26.5M | 0.15 |
| 2025-12-31 | $199.9M | -$59.0M | -$47.5M | $170.2M | -$51.1M | — |
| 2025-09-30 | $458.6M | $215.7M | $227.9M | $434.0M | $223.2M | 1.71 |
| 2025-06-30 | $178.5M | -$42.2M | -$30.1M | $164.9M | -$33.3M | -0.33 |
| 2025-03-31 | $166.8M | -$92.2M | -$80.4M | $132.4M | -$83.3M | -0.74 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-04-29 | BAUMAL CAROLINE | Officer | 900 | -- |
| 2026-04-17 | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 11,096 | -- |
| 2026-03-11 | FRANCOIS CEDRIC | Chief Executive Officer | 64,869 | -- |
| 2026-02-27 | DOLSTEN MIKAEL G | Director | 14,312 | -- |
| 2026-02-11 | DELONG MARK JEFFREY | Officer | 368 | $8.2K |
| 2026-02-03 | FRANCOIS CEDRIC | Chief Executive Officer | 8,840 | $33.2K |
| 2026-01-28 | NICHOLSON NUR | Chief Technology Officer | 45,220 | -- |
| 2026-01-28 | CHOPAS JAMES GEORGE | Officer | 16,150 | -- |
| 2026-01-28 | DELONG MARK JEFFREY | Officer | 36,606 | -- |
| 2026-01-28 | BOUCHER KELLEY | Officer | 30,146 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 13.5M | $555.4M | 0.1% |
| Wellington Management Group, LLP | 12.7M | $522.0M | 0.1% |
| Avoro Capital Advisors LLC | 12.2M | $501.5M | 0.1% |
| Morgan Stanley | 9.2M | $376.4M | 0.1% |
| Deep Track Capital, Lp | 7.8M | $318.0M | 0.1% |
| RTW Investments LP | 7.7M | $314.6M | 0.1% |
| UBS Group AG | 6.2M | $254.7M | 0.0% |
| Vanguard Portfolio Management LLC | 5.4M | $221.7M | 0.0% |
| Vanguard Capital Management LLC | 4.8M | $195.7M | 0.0% |
| State Street Corporation | 4.6M | $189.3M | 0.0% |
$5.3B
12.65
-0.246
13
$1.1B
$475.8M
2.88
1.15
0.1%
733
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-30 | $-0.33 | Pending | — |
| 2026-05-07 | $-0.36 | $0.15 | +141.3% |
| 2026-02-24 | $-0.39 | $-0.47 | -19.4% |
| 2025-10-30 | $0.94 | $1.67 | +77.3% |
| 2025-07-31 | $-0.47 | $-0.33 | +29.8% |
| 2025-05-07 | $-0.35 | $-0.74 | -114.4% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($40.92, 13 analysts) | |||
| 10 | $410.30 | +$-1.10 (-0%) | -0.0R |
| 50 | $2,051.50 | +$-5.50 (-0%) | -0.0R |
| 100 | $4,103.00 | +$-11.00 (-0%) | -0.0R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| CNTA | 0.394 |
| ALKS | 0.354 |
| RPI.L | 0.331 |
| ITRI | 0.299 |
| ARKG | 0.298 |
| Ticker | Correlation |
|---|---|
| CBNT | -0.236 |
| AMS | -0.234 |
| BCFC.BH | -0.217 |
| 1302.SR | -0.211 |
| WSBCO | -0.199 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.